Abstract:Introduction: Adoptive cell therapies using CAR T cells achieve great success in treating hematological malignances. Despite high complete response rates (70%-90%) in relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia with current CD19 CAR T cell therapies, 40%-60% of responders experience relapse with up to 60% due to CD19 antigen loss. Similarly, despite high initial response rates in CAR T cell treated r/r multiple myeloma patients, most eventually experience disease progression with relapses due to antigen loss. Dual targeting approaches combining two tumor antigens could overcome these limitations and increase treatment effectiveness. CAR T cell therapies commonly rely on lentiviral vectors for CAR T cell engineering. While these viral vectors can provide high transduction efficiencies, they have limited genetic cargo capacity, oncogenicity safety concerns, and high manufacturing cost and complexity. To address these shortcomings, we developed a non-viral delivery approach using a bioengineered mammalian transposase derived from the mammal, Myotis lucifugus (bMLT) that efficiently integrates large DNA cargo (>100 kb). Unlike gene editing, this system inserts new DNA into human T cells without causing double-strand DNA breaks or needing host DNA repair. Here, we show the ex vivo and in vivo efficacy of this platform to generate dual CAR T cells to overcome antigen loss in hematological malignancies. Methods: Dual CAR T cells targeting CD19/CD22 or BCMA/GPRC5D antigens were generated by delivering a DNA dual CAR cargo (>7.4 kb) and bMLT mRNA to T cells by an optimized electroporation protocol. CAR-expressing T cells were enriched and expanded in the presence of methotrexate. CAR expression, CD4 and CD8 T cell frequencies, and memory and exhaustion phenotypes were analyzed by flow cytometry. CAR T cell potency was assessed using a luciferase-based cytotoxicity assay at different E:T ratios and by measuring the release of IFNγ, TNFα, and GZMB in tumor co-culture assays. In vivo efficacy was evaluated in a Raji lymphoma xenograft mouse model, where tumor antigen loss was simulated by co-injecting a small number of CD19-KO Raji cells. Results: Our transposon technology achieved over 70% stable dual CAR T expression with a high frequency of Tscm/Tcm cells (>65%), low exhaustion markers expression (<2% co-expressing PD-1, TIM-3, and LAG-3), and efficient killing and IFNγ release in tumor co-cultures. Importantly, the dual CD19/CD22 CAR T cells, unlike single-targeting CD19 CAR T cells, were highly efficacious in vivo against dual antigen-expressing Raji cells but completely abrogated tumor growth against a mix of wild-type and CD19-KO Raji cells. Conclusions: Our bioengineered mammalian transposon technology efficiently generates potent dual-targeting CAR T cells with an optimal immunophenotype profile that overcomes tumor antigen loss in vivo. This technology can surpass the cargo capacity and other limitations of viral vectors, enabling more complex CAR T cell designs for cancer immunotherapy. Citation Format: Francisco Navarro, Amanda Vandeveer, Joshua LaMora, Javier García-Vilas, Priya Viswanathan, Joseph J Higgins. A bioengineered mammalian transposon for dual targeting CAR T cells: Addressing antigen escape in hematological cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B042.

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Engineering strategies to safely drive CAR T-cells into the future

Universal CARs, universal T cells, and universal CAR T cells

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation

Universal CAR cell therapy: Challenges and expanding applications

Super-resistant CAR Ts take on cancers

CAR T cells: Building on the CD19 paradigm

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Abstract 1330: Universal and potent chimeric antigen receptor-natural killer (upCAR-NK) cells for B-cell malignancy treatment

In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism.

Abstract B042: A bioengineered mammalian transposon for dual targeting CAR T cells: Addressing antigen escape in hematological cancers

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Genome-wide CRISPRa screens nominate modulators of CAR T cell survival within distinct tumor cytokine milieus

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy